InspireMDSTU:II2 +2.46%47 Forward PE Ratio is 0.00 as of Jul. 12, 2026. GuruFocus rates STU:II2 with a GF Score™ of 47/100 and a GF Value™ of €1.50 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 392 Medical Devices & Instruments companies, InspireMD ranks worse than 255101.79% on this metric.
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
InspireMD Forward PE Ratio Related Terms
InspireMD Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for InspireMD's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InspireMD Forward PE Ratio Chart
InspireMD Annual Data
Trend
2019-12
Forward PE Ratio
9.54
InspireMD Quarterly Data
2019-09
2019-12
2020-03
Forward PE Ratio
24.88
9.54
9.26
STU:II2 vs TELA, BDMD, PAVM: Forward PE Ratio Comparison
For the Medical Devices subindustry, InspireMD's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InspireMD Forward PE Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, InspireMD's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where InspireMD's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
InspireMD (STU:II2) has a Forward PE Ratio of 0.00 as of Jul. 12, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on InspireMD and its competitors. According to the industry distribution chart, InspireMD ranks #999999 out of 392 companies in the Medical Devices & Instruments industry.
Is InspireMD's Forward PE Ratio too high?
InspireMD's current Forward PE Ratio is 0.00. Based on the distribution chart, InspireMD ranks #999999 out of 392 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, InspireMD has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InspireMD's Forward PE Ratio compare to TELA and BDMD?
According to the Medical Devices & Instruments industry distribution chart, InspireMD ranks #999999 out of 392 companies for Forward PE Ratio. This places InspireMD in the lower half of its industry. The industry median Forward PE Ratio is 19.14. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Devices & Instruments company?
The median Forward PE Ratio among Medical Devices & Instruments companies is 19.14, based on 392 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on InspireMD and its competitors. For the Medical Devices & Instruments industry, the median Forward PE Ratio is 19.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InspireMD's current Forward PE Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InspireMD stock overvalued right now?
Based on GuruFocus' analysis, InspireMD (STU:II2) is currently considered Possible Value Trap. The stock's GF Value™ is €1.50, compared to a current price of €0.63 — trading 58.3% below its estimated fair value. The current Forward PE Ratio is 0.00. InspireMD's overall GF Score™ is 47/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For InspireMD (STU:II2), the current Forward PE Ratio is 0.00 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InspireMD (STU:II2) Overvalued in 2026?
Based on GuruFocus' analysis, InspireMD stock appears to be undervalued.
The current stock price of €0.63 is trading 58.3% below its estimated GF Value™ of €1.50.
GuruFocus considers InspireMD to be Possible Value Trap.
Key valuation signals for STU:II2:
Forward PE Ratio: 0.00
GF Value™: €1.50 vs. price of €0.63 (58.3% below fair value)
No single metric tells the full story. See the STU:II2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.
47GF Score
Get the complete analysis for STU:II2
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:II2 has been successfully added to your 